Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.

Science signaling - 2 Dec 2014

Littlefield Peter, Liu Lijun, Mysore Venkatesh, Shan Yibing, Shaw David E, Jura Natalia

Abstract excerpt

The human epidermal growth factor receptor (HER) tyrosine kinases homo- and heterodimerize to activate downstream signaling pathways. HER3 is a catalytically impaired member of the HER family that contributes to the development of several human malignancies and is mutated in a subset of cancers. HER3 signaling depends on heterodimerization with a catalytically active partner, in particular epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cloning, Molecular
Share to Crystallization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to ErbB Receptors

Share to Molecular Dynamics Simulation

Share to Mutagenesis, Site-Directed

Share to Protein Structure, Tertiary

Share to Receptor, ErbB-3

Source

Open in PubMed Open full text

Identifiers

PMID: 25468994
DOI: 10.1126/scisignal.2005786
PMCID: PMC4492339

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.PMID 25468994Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

Advances in Targeting HER3 as an Anticancer TherapySemantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

Structures of the active HER2/HER3 receptor complex reveal dynamics at the dimerization interface induced by binding of a single ligandSemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

Activating HER3 mutations in breast cancerSemantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface.Semantic proximity Read ↗

Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.Semantic proximity Read ↗

Thirty Years of HER3: From Basic Biology to Therapeutic InterventionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.